Through predicting the efficacy of treatments for individuals OncoFINDER™ has the potential to generate substantial healthcare savings and increase availability of expensive oncology medications to those who can benefit from them most.
Hong Kong, P.R.C. (PRWEB) April 03, 2014
Pathway Pharmaceuticals announced today that it is to launch a Personalized Cancer Treatment Service to enable medical professionals to predict the efficacy of therapies for individual cancer patients. The service tests drugs that are approved by national regulatory agencies on gene expression in patient tumour biopsies using the OncoFINDER™ tool. It can also be used to analyze the efficacy of treatments currently in clinical trials and in the laboratory.
OncoFINDER™ predicts drug efficacy by comparing the gene expression data from patient tumor biopsies against tissue-specific genomic profiles collected from healthy donors over 7 years by an international team of scientists. The proprietary efficacy prediction algorithms were developed by bio-mathematicians at the Moscow Institute of Physics & Technology.
Results generated by OncoFINDER™ are expected to enable medical professionals to prescribe treatments more effectively and have the potential to reduce healthcare costs for companies and governments. In the United Kingdom the National Institute of Health and Care Excellence is responsible for recommending whether a treatment be available on the National Health Service following a cost-benefit analysis. An increase in effective prescription of therapies could lead to an increase in the availability of expensive oncology therapies where cost currently limits use.
The ability of OncoFINDER™ to predict the efficacy of various compounds may significantly improve the outcomes of clinical trials for many pharmaceutical companies by helping make better enrollment decisions.
“Every year more and more effective and promising cancer treatments reach the clinic and the pace of drug discovery is expected to accelerate. Unfortunately, in addition to high cost, many of the targeted drugs are not effective in many individual patients. Prescribing these drugs often results in patients wasting valuable time, money and often lives. Today we are happy to see that the many years of hard work by hundreds of my colleagues in both science and medicine have culminated in a truly international venture dedicated to improve survival rates by helping oncologists around the world make better decisions when prescribing the targeted drugs to their patients.” said Professor Anton Buzdin PhD, DSc, Pathway Pharmaceuticals CEO.